New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
06:41 EDTSAGESage Therapeutics receives fast track designation for SAGE-547
SAGE Therapeutics announced that the FDA has granted fast track designation to the SAGE-547 development program. SAGE-547 is an allosteric modulator of GABAA receptors in development for the treatment of adult patients with refractory status epilepticus who have not responded to standard regimens. SAGE is currently evaluating SAGE-547 in a Phase 1/2 clinical trial for the treatment of SRSE. Preliminary data indicate that the first four patients enrolled in the clinical trial met the key efficacy endpoint, in that each was successfully weaned off his or her anesthetic agent while SAGE-547 was being administered. There have also been no reported drug-related serious adverse events in these four patients to date.
News For SAGE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
07:24 EDTSAGESAGE Therapeutics price target raised to $85 from $58 at Canaccord
Subscribe for More Information
May 19, 2015
07:28 EDTSAGEUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
May 15, 2015
10:01 EDTSAGEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:54 EDTSAGESAGE Therapeutics data 'impressive,' says SunTrust
Subscribe for More Information
05:47 EDTSAGESAGE Therapeutics initiated with a Buy at Goldman
Subscribe for More Information
May 14, 2015
06:33 EDTSAGESage Therapeutics sees cash and cash equivalents sufficient through mid-2017
Subscribe for More Information
06:32 EDTSAGESage Therapeutics reports Q1 EPS (66c), consensus (49c)
Subscribe for More Information
06:19 EDTSAGESage Therapeutics' epilepticus candidate shows positive Phase 1/2 results
Subscribe for More Information
May 13, 2015
15:05 EDTSAGENotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use